Pfizer signed a research collaboration and licensing agreement with Enodia Therapeutics that gives the pharma a stake in Sec61 inhibition programs. Under the deal, Enodia will run discovery work to screen and optimize Sec61 inhibitor candidates across multiple collaboration targets, with Pfizer handling later clinical development, manufacturing, regulatory, and commercial activities. Enodia will receive an undisclosed upfront payment and milestone-based compensation; the deal’s potential value is estimated at more than $500 million. The therapeutic premise centers on selectively modulating Sec61, a key channel controlling co-translational protein translocation, to block disease-driving proteins at the point of synthesis. Strategically, the collaboration adds a major Western pharma platform bet into a target class that has been attracting more attention for intracellular “protein biogenesis” control. Investors will watch how quickly Enodia advances lead candidates and how Pfizer translates platform screening into clinical-quality profiles.